

Calgary
Type A Continuing Care Home Formulary
Pharmacy and Therapeutics Committee

Last Name (Legal)		First Name (Legal)	
Preferred Name ☐ Last ☐ First		DOB(dd-Mon-yyyy)	
PHN	ULI ☐ Same as PHN	MRN	
Administrative Gender ☐ Male ☐ Female		☐ Non-binary/Prefer not to disclose (X) ☐ Unknown	

COMPOUND MEDICATION FUNDING REQUEST

Form submission is required within the 3 weeks grace period following admission/readmission to a Type A Continuing Care Home (CCH). For new starts at the CCH, form submission is required before initial drug provision.

Processing Instructions: Please complete the form in its entirety, and submit via secure encrypted email emails to the ISFL Type A CCH Pharmacist at:

cc.drugmanagement@albertahealthservices.ca OR the pharmacist or physician can fax it to **403-943-0232**

☐ **NEW request** ☐ **TRIAL renewal** ☐ **OTHER renewal**

Resident Code: ⁱ	Date of Birth:	Type A Continuing Care Home:
Drug name/Compound Name (name, formulation, route):		Dose/Regimen:
Physician:	Expected Duration of Therapy:	Daily Drug Cost: OR Total Price of Compound:
Is this a high cost non-formulary request ⁱⁱ ? ☐ Yes ☐ No		
Does the Resident have alternate funding that covers the medication? ☐ Yes ☐ No		
If yes, please specify:		

Section A - Assessment, Monitoring and Outcomes

1. ☐ New Request	
Indication for Use/Reason for Prescribing (include references and citations used if applicable):	
Relevant Medical History:	
Trials of Formulary (or Non-Formulary Alternatives and Outcomes of Trials):	
Expected Outcome of Therapy/Measures of Success, and Monitoring Parameters:	
Additional Details (as applicable):	
2. ☐ Trial renewal – Initial trial duration: Trial effect/Outcome/Benefit:	Previous Approval Code:
3. ☐ OTHER renewal Update on Resident Status/Monitoring Parameters/Other Detail:	Previous Approval Code:

Section B - Compound Information

Compound Composition, ingredient details and cost *may attach as separate sheet*	
Ingredient Name (including base)	Ingredient Strength
Total Quantity (optimized based on use & stability):	
Estimated Days' Supply:	Shelf-Life/Stability Dating:
Are there any commercially available alternatives (include consideration of different drug, dose, formulation with expected similar therapeutic effect)? ☐ Yes ☐ No	
Rationale for compound funding request. Check all that apply ⁱⁱⁱ .	

Calgary

Type A Continuing Care Home Formulary

Pharmacy and Therapeutics Committee

Last Name <i>(Legal)</i>		First Name <i>(Legal)</i>	
Preferred Name ☐ Last ☐ First		DOB <i>(dd-Mon-yyyy)</i>	
PHN	ULI ☐ Same as PHN	MRN	
Administrative Gender ☐ Male ☐ Female ☐ Non-binary/Prefer not to disclose (X) ☐ Unknown			

☐	Change in dosage form or strength of a Formulary drug
☐	To replace a Formulary drug unavailable due to a supply issue
☐	Contraindication or intolerance to commercially available alternative
☐	Lack of efficacy of Formulary or commercially available alternative
☐	Other ⁱⁱⁱ

THIS SECTION FOR CLINICAL PHARMACIST/PHARMACY PROVIDER USE ONLY

Must be completed prior to submission

Pharmacist's Name:	Phone:
Request Date:	Initial Date of Drug Provision ^{iv} :

THIS SECTION IS FOR ALBERTA HEALTH SERVICES USE ONLY

Outcome:
Approval Code: Approval type: Date:

ⁱ First four letters of surname followed by first two letters of given name

ⁱⁱ A high cost non-formulary drug is any drug not listed or used in accordance with Formulary criteria that costs more than \$250 per month or \$230 per dispense

ⁱⁱⁱ Compounds ineligible for coverage

- Compounds created for cosmetic purposes
- Compounds that duplicate the effect of an existing pharmaceutical product
- Compounds with unproven effects. Example: topical compounded pain preparation containing ingredients where available scientific evidence demonstrating clinical efficacy and safety is limited

^{iv} The date the pharmacy provider started providing the drug